group VI iPLA₂ (T-14): sc-14463



The Power to Question

BACKGROUND

Phospholipases catalyze the release of fatty acids from phospholipids. One member of the phospholipase family, iPLA2, is detected as a membrane-bound protein with multiple smaller isoforms, which result from alternative splicing. Two isoforms, Ankyrin- iPLA2-1 and -2, lack the catalytic domain and are thought to be involved in the negative regulation of iPLA2 activity. The SH-iPLA2 isoform is cytoplasmically localized. The human gene encoding iPLA2 maps to chromosome 22q13.1. Another phopholipase, sPLA2, belongs to a family of secretory phospholipases A2, which represent an expanding family of related enzymes. sPLA2 has both membrane bound and secreted forms that are encoded by a single gene. sPLA2 is involved in the regulation of phospholipid metabolism in biomembranes and in eicosanoid biosynthesis.

CHROMOSOMAL LOCATION

Genetic locus: PLA2G6 (human) mapping to 22q13.1; Pla2g6 (mouse) mapping to 15 E1.

SOURCE

group VI iPLA₂ (T-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the C-terminus of iPLA₂ of human origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with <0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-14463 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

group VI iPLA $_2$ (T-14) is recommended for detection of calcium-independent PLA $_2$ of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

group VI iPLA $_2$ (T-14) is also recommended for detection of calcium-independent PLA $_2$ in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for group VI iPLA $_2$ siRNA (h): sc-43819, group VI iPLA $_2$ siRNA (m): sc-43820, group VI iPLA $_2$ shRNA Plasmid (h): sc-43819-SH, group VI iPLA $_2$ shRNA Plasmid (m): sc-43820-SH, group VI iPLA $_2$ shRNA (h) Lentiviral Particles: sc-43819-V and group VI iPLA $_2$ shRNA (m) Lentiviral Particles: sc-43820-V.

Molecular Weight of group VI iPLA₂: 88 kDa.

Positive Controls: group VI iPLA $_2$ (h): 293T Lysate: sc-116309, group VI iPLA $_2$ (m2): 293T Lysate: sc-120641 or rat testis extract: sc-2400.


STORAGE


Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA





group VI iPLA₂ (T-14): sc-14463. Western blot analysis of group VI iPLA₂ expression in non-transfected: sc-117752 (**A**) and mouse group VI iPLA₂ transfected: sc-120641 (**B**) 293T whole cell lysates.

group VI iPLA $_2$ (T-14): sc-14463. Western blot analysis of group VI iPLA $_2$ expression in non-transfected: sc-117752 ($\bf A$) and mouse group VI iPLA $_2$ transfected: sc-120641 ($\bf B$) 293T whole cell lysates.

SELECT PRODUCT CITATIONS

- Mangikian, A.D., et al. 2004. Cell cycle dependence of group VIA calciumindependent phospholipase A₂ activity. J. Biol. Chem. 279: 52881-52892.
- Zhang, X.H., et al. 2006. Disruption of G₁-phase phospholipid turnover by inhibition of Ca²⁺-independent phospholipase A₂ induces a p53-dependent cell-cycle arrest in G₁ phase. J. Cell Sci. 119: 1005-1015.
- Kolko, M., et al. 2007. Identification of intracellular phospholipases A₂ in the human eye: involvement in phagocytosis of photoreceptor outer segments. Invest. Ophthalmol. Vis. Sci. 48: 1401-1409.
- 4. Kuwata, H., et al. 2007. A novel role of group VIB calcium-independent phospholipase A_2 (iPLA $_{2\gamma}$) in the inducible expression of group IIA secretory PLA $_2$ in rat fibroblastic cells. J. Biol. Chem. 282: 20124-20132.
- Amanchy, R., et al. 2009. Identification of c-Src tyrosine kinase substrates in platelet-derived growth factor receptor signaling. Mol. Oncol. 3: 439-450.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.



Try **group VI iPLA₂ (D-4): sc-376563** or **group VI iPLA₂ (E-8): sc-166616**, our highly recommended monoclonal alternatives to group VI iPLA₂ (T-14).

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com